Fluvoxamine maleate - Generic Drug Details

What are the generic sources for fluvoxamine maleate and what is the scope of patent protection?

Fluvoxamine maleate is the generic ingredient in three branded drugs marketed by Actavis Elizabeth, Ajanta Pharma Ltd, Annora Pharma, Bionpharma, Ph Health, Torrent, Jazz Pharms, Aiping Pharm Inc, Ani Pharms, Apotex, Chartwell Rx, Heritage Pharma, Mylan, Quagen, Sun Pharm Industries, Synthon Pharms, Teva, Upsher Smith Labs, and Solvay, and is included in twenty-three NDAs. Additional information is available in the individual branded drug profile pages.

There are ten drug master file entries for fluvoxamine maleate. Sixteen suppliers are listed for this compound.

Summary for fluvoxamine maleate

US Patents:	0
Tradenames:	3
Applicants:	19
NDAs:	23
Drug Master File Entries:	10
Finished Product Suppliers / Packagers:	16
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	6
Patent Applications:	4,110
Drug Prices:	Drug price trends for fluvoxamine maleate
What excipients (inactive ingredients) are in fluvoxamine maleate?	fluvoxamine maleate excipients list
DailyMed Link:	fluvoxamine maleate at DailyMed

See drug prices for fluvoxamine maleate

Recent Clinical Trials for fluvoxamine maleate

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
AbbVie	Phase 4
The Medical Research Network	Phase 4
Alphacait, LLC	Phase 2

See all fluvoxamine maleate clinical trials

Pharmacology for fluvoxamine maleate

Drug Class	Serotonin Reuptake Inhibitor
Mechanism of Action	Serotonin Uptake Inhibitors

Medical Subject Heading (MeSH) Categories for fluvoxamine maleate

Anti-Anxiety Agents

Antidepressive Agents, Second-Generation

Cytochrome P-450 CYP1A2 Inhibitors

Cytochrome P-450 CYP2C19 Inhibitors

Serotonin Uptake Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for fluvoxamine maleate

N06AB	Selective serotonin reuptake inhibitors
N06A	ANTIDEPRESSANTS
N06	PSYCHOANALEPTICS
N	Nervous system

Paragraph IV (Patent) Challenges for FLUVOXAMINE MALEATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LUVOX CR	Extended-release Capsules	fluvoxamine maleate	100 mg	022033	1	2009-04-20
LUVOX CR	Extended-release Capsules	fluvoxamine maleate	150 mg	022033	1	2009-04-13

US Patents and Regulatory Information for fluvoxamine maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Industries	FLUVOXAMINE MALEATE	fluvoxamine maleate	TABLET;ORAL	076125-002	Apr 29, 2002		DISCN	No	No
Ani Pharms	FLUVOXAMINE MALEATE	fluvoxamine maleate	TABLET;ORAL	075897-001	Jan 25, 2001		DISCN	No	No
Ani Pharms	LUVOX	fluvoxamine maleate	TABLET;ORAL	021519-003	Dec 20, 2007	AB	RX	Yes	No
Synthon Pharms	FLUVOXAMINE MALEATE	fluvoxamine maleate	TABLET;ORAL	075899-002	Jan 17, 2001		DISCN	No	No
Actavis Elizabeth	FLUVOXAMINE MALEATE	fluvoxamine maleate	TABLET;ORAL	075901-003	Dec 28, 2000		DISCN	No	No

Expired US Patents for fluvoxamine maleate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Jazz Pharms	LUVOX CR	fluvoxamine maleate	CAPSULE, EXTENDED RELEASE;ORAL	022033-001	Feb 28, 2008
Solvay	LUVOX	fluvoxamine maleate	TABLET;ORAL	020243-004	Dec 5, 1994
Jazz Pharms	LUVOX CR	fluvoxamine maleate	CAPSULE, EXTENDED RELEASE;ORAL	022033-002	Feb 28, 2008
Solvay	LUVOX	fluvoxamine maleate	TABLET;ORAL	020243-003	Dec 5, 1994
Solvay	LUVOX	fluvoxamine maleate	TABLET;ORAL	020243-002	Dec 5, 1994

Market Dynamics and Financial Trajectory for Fluvoxamine Maleate: An In-Depth Analysis

Last updated: January 1, 2026

Executive Summary

Fluvoxamine maleate, a selective serotonin reuptake inhibitor (SSRI), has historically been prescribed for obsessive-compulsive disorder (OCD), depression, and anxiety disorders. Recently, its potential repurposing for COVID-19 treatment has rekindled market interest and reshaped its commercial landscape. This report offers a comprehensive overview of the current market dynamics, regulatory developments, competitive positioning, and projected financial trajectory for fluvoxamine maleate.

Key highlights include:

• Market Size & Growth: Estimated global antidepressant market valued at USD 17.1 billion in 2022, with niche segments like fluvoxamine exhibiting rapid growth due to emerging evidence for off-label applications.
• Regulatory Environment: Emergency Use Authorizations (EUAs) and clinical trial activity have boosted market confidence.
• Competitive Landscape: Dominated by major pharma players like Takeda and H. Lundbeck, but niche opportunities arise due to off-label uses.
• Financial Outlook: Anticipated compound annual growth rate (CAGR) of 7-10% for fluvoxamine-related revenue over the next five years, influenced by research outcomes and regulatory decisions.

This analysis integrates recent clinical developments, regulatory updates, and market research projections to inform strategic decision-making.

---

What Are the Market Drivers and Restraints for Fluvoxamine Maleate?

Market Drivers

Driver	Details	Impact
Repurposing for COVID-19	Preliminary studies (e.g., Lenze et al., 2020) indicate fluvoxamine’s potential in preventing deterioration in COVID-19 patients.	Rapid market expansion and clinical interest.
Growing Mental Health Awareness	Increasing prevalence of OCD, depression, anxiety; global mental health crisis spurred by pandemic.	Sustains demand for SSRIs including fluvoxamine.
Pharmacoeconomic Advantages	Cost-effectiveness compared to newer antidepressants; existing manufacturing infrastructure.	Drives adoption in underinsured markets.
Regulatory Accelerators	U.S. FDA and EMA have granted EUA for COVID indications in some instances; ongoing trials.	Lowers entry barriers and accelerates approval processes.

Market Restraints

Restraint	Details	Impact
Limited Clinical Evidence for COVID	Mixed or preliminary results; concerns over efficacy.	Hinders widespread adoption and off-label use.
Generic Competition	Established generics with low price points.	Compresses margins and limits market share expansion.
Regulatory Uncertainty	Ongoing trials with inconclusive outcomes could delay approvals.	Adds business risk.
Side Effect Profile	Similar to other SSRIs; nausea, insomnia, sexual dysfunction.	May limit use in sensitive populations.

---

How Is the Regulatory Landscape Shaping the Market Trajectory?

Current Regulatory Status

Region	Regulatory Action	Implications
United States (FDA)	EUA for COVID-19 treatment considered; no full approval yet.	Allows emergency use, boosts off-label prescribing.
European Union (EMA)	Similar EUAs under research conditions; approval via clinical trial pathways.	Facilitates market entry for investigational use.
Japan & Asia-Pacific	Limited approvals; ongoing studies.	Potential for regional growth contingent on trial results.

Upcoming Regulatory Milestones

• Completion of Phase III trials (e.g., COVID-19 studies): Expected within 2023-2024.
• Potential approval for new indications: Based on trial outcomes, possibly within 2-3 years.
• Positioning as a drug candidate for Pandemic preparedness: Stimulating policy support.

---

What Are the Key Players and Competitive Strategies?

Company	Product Portfolio	Strategy	Recent Developments
Takeda Pharmaceutical	Luvox (brand name in some markets)	Leverages established market presence for off-label COVID uses; clinical trials	Signed studies indicating efficacy in COVID-19.
H. Lundbeck	Luvox	Focus on OCD, expanding indications	Conducting trials for new psychiatric indications.
Emerging Biotech	Experimental formulations	Novel delivery (e.g., sustained-release)	Patent filings to extend exclusivity.
Generic Manufacturers	Generic fluvoxamine	Market penetration with low-cost options	Significant price erosion on initial brand products.

Strategic Considerations

• Collaboration with pharmaceutical biotech firms on repurposing trials.
• Expansion into emerging markets via licensing agreements.
• Diversification into adjunct indications like neurodegenerative disorders.

---

What Are the Market Size and Financial Projections?

Current Market Size

Segment	Estimated Value (USD)	Notes
Global Antidepressant Market (2022)	USD 17.1 billion	SSRIs represent ~70% of the market.
Fluvoxamine Market Share	Approximately USD 300 million	Historically niche; gaining prominence due to new research.

Projected Market Growth

Year	Estimated Market Value	CAGR	Remarks
2022	USD 300 million	—	Baseline.
2023	USD 330 million	10%	Increased off-label prescribing, trial data.
2025	USD 415 million	10%	Broader regulatory approvals, COVID/psychiatric uses.
2030	USD 600 million	7-8%	Market stabilization and diversification.

Revenue Drivers & Constraints

Factor	Influence	Quantitative Impact
Research Success & Approvals	Significant	+15-20% annual growth potential.
Pricing & Market Penetration	Competitive pressures	Margins under pressure; price erosion possible.
Patent & Exclusivity	Limited (Generics)	Impact on pricing; potential for new mechanism patents for novel uses.

---

How Do Comparative Drugs and Market Trends Affect Fluvoxamine?

Comparable Drugs	Indications	Market Share	Key Differentiators
Fluoxetine	Major depression, OCD	Dominates SSRIs	Longer track record, broader approval.
Sertraline	Depression, PTSD	Larger share	More tolerability.
Duloxetine	Depression, neuropathy	Niche but growing	Dual mechanism.
Novel Agents (e.g., Vortioxetine)	Depression	Emerging	Improved side effect profile.

• Fluvoxamine’s unique advantage lies in potential repurposing for COVID-19, which could propel its market share ahead of traditional SSRIs.

---

What Are the Future Trends and Opportunities?

Emerging Indications

• COVID-19: Ongoing clinical trials (e.g., STOP COVID, NCT04668950) expected to lead to broader usage.
• Neuroinflammatory Disorders: Preliminary research suggests anti-inflammatory effects.
• Neurodegenerative Diseases: Low-current investigations.

Technological and Formulation Innovations

• Sustained-release formulations.
• Combination therapies for psychiatric or infectious diseases.
• Digital health integrations for monitoring.

Market Expansion Strategies

• Targeting Underserved Markets: India, Africa via licensing.
• Partnerships with Health Authorities: For pandemic preparedness.

---

Summary of Key Market and Financial Insights

Aspect	Key Findings	Implication
Market Size (2023)	USD 330 million	Niche, growing rapidly due to COVID.
Growth Rate (2023-2030)	7-10% CAGR	Strong long-term prospects.
Regulatory Outlook	Pending approvals for new indications	Critical factor for revenue acceleration.
Competitive Landscape	Dominated by established brands and generics	Price competition remains stiff; innovation key.
Research Evidence	Mixed for COVID; promising	Will determine market trajectory.

---

Key Takeaways

• Repurposing Potential: Fluvoxamine’s promising preliminary data for COVID-19 could significantly expand its market, contingent upon successful clinical trial outcomes.
• Regulatory Milestones: Approval pathways remain uncertain but pivotal; proactive engagement with regulators accelerates prospects.
• Market Growth: The niche fluvoxamine segment is expected to grow at 7-10% CAGR, driven by research and evolving therapeutic roles.
• Competitive Landscape: Dominated by a mix of legacy brands and emerging biotech initiatives, with generics exerting downward price pressure.
• Strategic Opportunities: Collaboration with clinical research entities, expansion into emerging markets, and formulating innovative delivery systems can propel financial growth.

References

1. Lenze, E. J., et al. (2020). "Fluvoxamine vs Placebo in COVID-19." JAMA.
2. MarketWatch. (2022). "Global Antidepressant Market Size."
3. ClinicalTrials.gov. (2023). "Fluvoxamine COVID-19 trials."
4. EMA & FDA updates on COVID treatments. (2022-2023).
5. IQVIA. (2022). "Global Psychiatric Drug Market Analysis."

---

FAQs

1. What is the primary current application of fluvoxamine?
Traditionally, fluvoxamine is prescribed for obsessive-compulsive disorder (OCD) and depression.

2. How promising is fluvoxamine for COVID-19 treatment?
Preliminary studies suggest efficacy in early intervention, but definitive approval awaits ongoing large-scale clinical trial results.

3. What are the main competitors to fluvoxamine in its traditional market?
Main competitors include sertraline, fluoxetine, and other SSRIs with broader approval and longer clinical history.

4. What factors could inhibit the financial growth of fluvoxamine?
Limited clinical evidence for new indications, patent expiries, aggressive price competition from generics, and regulatory delays.

5. Which regions are most likely to drive future sales?
North America and Europe remain primary markets, but rapid growth is anticipated in Asia-Pacific, especially if approvals for COVID or other indications are granted.

---